-
Mashup Score: 3A Story of Hope For Kids With Rare Disease - TimmermanReport.com - 14 hour(s) ago
As we head into Thanksgiving, I wanted to share a story that highlights the promise and possibility that can emerge from a devastating diagnosis, and emphasizes what can happen when industry, academia, and — especially — impassioned parents and advocates join forces. Consider the devasting rare genetic disease, spinal muscular atrophy, or SMA. According to… Read More
Source: timmermanreport.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4
“Does the crowd understand? Is it East versus West Or man against man? Can any nation stand alone?” Burning Heart, by Survivor – Rocky IV In national politics, the culture wars may pit the coasts against the rest of the country. In biotech, however, the AI culture war seems to pit the coasts against each… Read More
Source: timmermanreport.comCategories: General Medicine News, General HCPsTweet-
I write about the coastal culture class in AI+biotech in my latest @timmermanreport , h/t @Chandanananana @LifeSciVC and the glorious 1980s. https://t.co/q8Cu2bYiQu cc @adamjshay @zakkohane @ScottGottliebMD @VentureValkyrie
-
-
Mashup Score: 2Third Rock-backed Trace Neuroscience Debuts with $101M, RNA Drug for ALS - TimmermanReport.com - 13 day(s) ago
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Source: timmermanreport.comCategories: General Medicine News, General HCPsTweet-
Poignant as well as characteristically thoughtful coverage of launch of newco Trace Neuroscience (targeting ALS) by @ldtimmerman @timmermanreport , who lost his grandmother to this horrible disease: https://t.co/YNUbXfZFV1 - ~all top-tier early stage LS VCs seem represented
-
-
Mashup Score: 5And Just Like That: What the Viral Adoption of a Clinical AI App Means for Pharma R&D - TimmermanReport.com - 24 day(s) ago
In 2011, we were experiencing the ascension of technologies like the cloud and the smartphone. Apps had become a thing: social network apps like Instagram (the iPhone “App of the Year” in 2011) and Twitter, utility apps like Evernote and Dropbox, navigation apps like Google Maps and Waze, and game apps like Angry Birds. Yet… Read More
Source: timmermanreport.comCategories: General Medicine News, General HCPsTweet-
In latest @timmermanreport, I describe AI chasm in pharma R&D, the deep skepticism towards AI among seasoned R&D scientists, & how rapid adoption of clinical AI platform @EvidenceOpen shows how fast things can change https://t.co/e5vsxZgIRm @zakkohane @emollick @ScottGottliebMD
-
-
Mashup Score: 5And Just Like That: What the Viral Adoption of a Clinical AI App Means for Pharma R&D - TimmermanReport.com - 25 day(s) ago
In 2011, we were experiencing the ascension of technologies like the cloud and the smartphone. Apps had become a thing: social network apps like Instagram (the iPhone “App of the Year” in 2011) and Twitter, utility apps like Evernote and Dropbox, navigation apps like Google Maps and Waze, and game apps like Angry Birds. Yet… Read More
Source: timmermanreport.comCategories: General Medicine News, General HCPsTweet-
In latest @timmermanreport, I describe AI chasm in pharma R&D, the deep skepticism towards AI among seasoned R&D scientists, & how rapid adoption of clinical AI platform @EvidenceOpen shows how fast things can change https://t.co/e5vsxZgIRm @zakkohane @emollick @ScottGottliebMD
-
-
Mashup Score: 1
Two weeks ago, I wrote about how difficult it is for R&D leaders to “pick winners,” despite the enormous incentives to do so. I explained how we tend to underestimate the role of chance, and overestimate our ability to “domesticate uncertainty,” as Nassim Taleb and I wrote in the Financial Times in 2008. Mostly, efforts… Read More
Source: timmermanreport.comCategories: General Medicine News, General HCPsTweet-
Yes, human causal biology, rigorously applied, combined w good org structure/strong sci leadership/right size, can improve R&D PoS, eg $VRTX, $REGN. Also: emerging tech incl AI can+will contribute to next iteration of R&D elevation. In @timmermanreport https://t.co/zto2ZWzFhY
-
-
Mashup Score: 1Yes We Can: My Response To Skeptical Readers - TimmermanReport.com - 1 month(s) ago
Two weeks ago, I wrote about how difficult it is for R&D leaders to “pick winners,” despite the enormous incentives to do so. I explained how we tend to underestimate the role of chance, and overestimate our ability to “domesticate uncertainty,” as Nassim Taleb and I wrote in the Financial Times in 2008. Mostly, efforts… Read More
Source: timmermanreport.comCategories: General Medicine News, General HCPsTweet-
Yes, human causal biology, rigorously applied, combined w good org structure/strong sci leadership/right size, can improve R&D PoS, eg $VRTX, $REGN. Also: emerging tech incl AI can+will contribute to next iteration of R&D elevation. In @timmermanreport https://t.co/zto2ZWzFhY
-
-
Mashup Score: 20What If You Can’t Pick Winners in R&D? - TimmermanReport.com - 1 month(s) ago
Peter Thiel, the contrarian investor, had a favorite question for interviewees: “What important truth do few people agree with you on?” My answer: No one can pick winners in pharma R&D. When I think of the most significant blockbusters in the industry involving novel mechanisms of action (follow-ons are a different story), I see a… Read More
Source: timmermanreport.comCategories: General Medicine News, General HCPsTweet-
Latest @timmermanreport https://t.co/CdMBiWsPpO Rare, outsized success in biopharma R&D requires huge amt of luck+real skill. Key quality R&D leaders require=ability to muster conviction in face of overwhelming uncertainty. Plus: intense execution & ton of luck. @matthewherper
-
-
Mashup Score: 1Yes We Can: My Response To Skeptical Readers - TimmermanReport.com - 1 month(s) ago
Two weeks ago, I wrote about how difficult it is for R&D leaders to “pick winners,” despite the enormous incentives to do so. I explained how we tend to underestimate the role of chance, and overestimate our ability to “domesticate uncertainty,” as Nassim Taleb and I wrote in the Financial Times in 2008. Mostly, efforts… Read More
Source: timmermanreport.comCategories: General Medicine News, General HCPsTweet-
Yes, human causal biology, rigorously applied, combined w good org structure/strong sci leadership/right size, can improve R&D PoS, eg $VRTX, $REGN. Also: emerging tech incl AI can+will contribute to next iteration of R&D elevation. In @timmermanreport https://t.co/zto2ZWzFhY
-
-
Mashup Score: 6Can We Pick Winners With Causal Human Biology? Vertex Makes the Case - TimmermanReport.com - 1 month(s) ago
Everybody reading this column knows that biopharma is a difficult business. Biology is unfathomably complicated and figuring out how to introduce something into the human body that does more good than harm is a fiendishly difficult challenge. That’s why it’s important to recognize the occasional success. It reminds us what’s possible, and inspires us to… Read More
Source: timmermanreport.comCategories: General Medicine News, General HCPsTweet-
In her wonderful bk on complexity, @MelMitchell1 points out that even complexity experts can't seem to agree on what exactly the term means. I wonder if same is true for biopharma R&D leaders who now all seem to invoke "human causal biology"... https://t.co/Aep2ABbyrz @zakkohane
-
Just up at @timmermanreport - latest column celebrating a rare disease success story in SMA: https://t.co/2OwHMBcsz5 cc @smafoundation @zakkohane @adamjshay